10 Best Pharma Stocks to Buy for Long Term Growth
With big American pharmaceutical corporations always searching for medications in China, the US pharmaceutical industry is going through a unique trend never seen before.
Amneal Pharmaceuticals Inc. (AMRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 10,721,778 | $84,916,482 | 1.08% | |
| 2. | Citadel Investment Group Ken Griffin | 8,980,968 | $71,129,266 | +1% | 0.01% |
| 3. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 3,665,529 | $29,030,990 | +38% | 1.24% |
| 4. | Blackbarn Capital Jonathan Carter | 2,850,000 | $22,572,000 | +19% | 1.24% |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,541,058 | $12,205,179 | -26% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.21 | 50,000 | Director | 258,784 | 2021-12-17 | Filing | |
| $4.25 | 50,000 | Large Shareholder, Officer, Director | 512,566 | 2021-12-16 | Filing | |
| $4.13 | 100,000 | Large Shareholder, Officer, Director | 462,566 | 2021-12-15 | Filing | |
| $4.25 | 50,000 | Officer, Director | 512,566 | 2021-12-16 | Filing | |
| $4.13 | 100,000 | Officer, Director | 462,566 | 2021-12-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.30 | 80,000 | Director | 1,728,886 | 2025-04-01 | Filing | |
| $8.35 | 5,000,000 | 48,578,209 | 2025-03-14 | Filing | ||
| $8.89 | 125,000 | Officer | 290,106 | 2025-03-05 | Filing | |
| $8.73 | 46,936 | Officer | 32,606 | 2025-03-06 | Filing | |
| $8.88 | 43,064 | Officer | 79,542 | 2025-03-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,499,400 | $12,564,972 | 0.42% | |
| 2. | 819,736 | $6,869,388 | 0.01% | |
| 3. | 237,913 | $1,993,697 | 0% | |
| 4. | 119,820 | $1,004,092 | 0.03% | |
| 5. | 60,567 | $507,551 | 0% |
News See All
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2024 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2024 Earnings Call Transcript February 28, 2025Amneal Pharmaceuticals, Inc. misses on earnings expectations.
10 Best Weight Loss Drug Stocks to Buy According to Analysts
Most people have tried to include fitness and weight loss into their everyday routines.
12 Best Low Price Pharma Stocks To Invest In Right Now
Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the ...
10 Best Diabetes Stocks To Buy Under $10
About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income nations. Every year, diabetes directly causes 1.5 million deaths on average.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2024 Earnings Call Transcript
Operator: Hello, everyone and thank you for your patience. The Amneal Pharmaceuticals Third Quarter 2024 Earnings Call will begin shortly. [Operator Instructions] Thank you.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q2 2024 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q2 2024 Earnings Call Transcript August 9, 2024Amneal Pharmaceuticals, Inc. misses on earnings expectations.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2024 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.29824 EPS, expectations were $0.09. Amneal Pharmaceuticals, Inc.
11 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2023 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.14, expectations were $0.07.
Billionaire Hedge Funds
